午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

ofatumumab

ofatumumab Struktur
679818-59-8
CAS-Nr.
679818-59-8
Englisch Name:
ofatumumab
Synonyma:
ofatumumab;Ofatumumab (anti-CD20);Research Grade Ofatumumab;Research Grade Ofatumumab(DHC90701)
CBNumber:
CB91508605
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

ofatumumab Eigenschaften

Aggregatzustand
Liquid
Farbe
Colorless to light yellow

Sicherheit

Giftige Stoffe Daten 679818-59-8(Hazardous Substances Data)

ofatumumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Considered as the most common form of leukemia in adults, CLL is characterized by the accumulation of abnormal B lymphocytes and manifests itself as lymph node enlargement and bone marrow failure in symptomatic patients. Ofatumumab is the second marketed mAb to target CD20. Compared to its predecessor,it is a fully human mAb that was generated via transgenic mouse and hybridoma technology. In addition to the Fab portion that recognizes CD20, the Fc domain mediates immune effector functions to lyse cells via complement-dependent cytotoxicity (CDC) and antibody-dependent, cell-mediated cytotoxicity (ADCC). Ofatumumab targets a different, discontinuous epitope on CD20 than rituximab; it binds specifically to both the small and large extracellular loops of the CD20 molecule expressed on normal B lymphocytes and on B-cell CL, and its binding does not induce receptor internalization nor shedding from the cell surface. In addition to targeting a different epitope on CD20, ofatumumab also exhibits a slower off-rate. These characteristics have been proposed as reasons for its ability to lyse rituximab-resistant cells that express low levels of CD20 and for its greater in vitro activity against CLL cells versus rituximab.
The most common adverse events were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections.

Originator

Genmab (Denmark)

Trademarks

Arzerra

ofatumumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


ofatumumab Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 37)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
TargetMol Chemicals Inc.
+17819995354
marketing@targetmol.com United States 32296 58
TargetMol Chemicals Inc.

support@targetmol.com United States 38671 58
Wuhan Topule Biopharmaceutical Co., Ltd
+8618327326525
masar@topule.com China 8467 58
Aladdin Scientific

tp@aladdinsci.com United States 57505 58
LGM Pharma 1-(800)-881-8210
inquiries@lgmpharma.com United States 2123 70
Dalian Meilun Biotech Co., Ltd. 0411-62910999 13889544652
sales@meilune.com China 4747 58
NCE Biomedical Co.,Ltd. 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
China 1493 55
Shanghai EFE Biological Technology Co., Ltd. 021-65675885 18964387627
info@efebio.com China 9803 58
Shanghai YuanYe Biotechnology Co., Ltd. 021-61312847; 18021002903
3008007409@qq.com China 71826 60
ShangHai Biochempartner Co.,Ltd 177-54423994 17754423994
2853530910@QQ.com China 7990 62

679818-59-8()Verwandte Suche:


  • ofatumumab
  • Research Grade Ofatumumab(DHC90701)
  • Ofatumumab (anti-CD20)
  • Research Grade Ofatumumab
  • 679818-59-8
Copyright 2019 ? ChemicalBook. All rights reserved